United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027

United Therapeutics Corporation

UTHR

0.00

Approximately 200,000 patients in the United States have PPF, with limited treatment options

Topline data expected in the second half of 2027

United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.